RemeGen Co., Ltd. (HKG:9995)

Market Cap	15.52B
Revenue (ttm)	1.83B
Net Income (ttm)	-1.56B
Shares Out	537.91M
EPS (ttm)	-2.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,892,000
Average Volume	3,618,665
Open	17.94
Previous Close	17.98
Day's Range	17.12 - 18.86
52-Week Range	10.20 - 34.45
Beta	0.45
RSI	65.05
Earnings Date	Mar 28, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,615
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9995

Financial Performance

In 2023, RemeGen's revenue was 1.08 billion, an increase of 40.26% compared to the previous year's 772.11 million. Losses were -1.51 billion, 51.3% more than in 2022.

Financial numbers in CNY